Company intelligence / Profile preview

TAHO Pharmaceuticals

Ownership: Private
Employees: ~24
Development stage: Phase 3

Overview

TAHO has successfully commercialized innovative drug delivery products such as Ondansetron OD Film in Japan for chemotherapy-induced nausea/vomiting. The company’s pipeline includes multiple late-stage programs leveraging its proprietary TDS platform to address unmet needs in CNS disorders, anticoagulation/thrombosis prevention, opioid addiction/overdose management, and pediatric indications. Several programs are at Phase 1 or NDA stage; some have market exclusivity as first-in-class dosage forms.

Therapeutic areas: PsychiatryOncologyCardiovascular
Modalities: Small moleculesOral dissolving films (ODF)Transdermal patchesSublingual and buccal filmsOral liquids
Industry: Biotech

Drug pipeline

3 assets

atomoxetine (Taihe Pharmaceutical)

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Mithradote Bio（co-led seed round investment/development agreement）

Beyond the preview

Go deeper on TAHO Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAHO Pharmaceuticals.

Explore the full profile